605680-35-1

Basic information

• Product Name: Propanoic acid, 2-(2-fluorophenoxy)-2-Methyl-
• Synonyms: Propanoic acid, 2-(2-fluorophenoxy)-2-Methyl-;2-(2-fluorophenoxy)-2-methylPropanoic acid
• CAS NO: 605680-35-1
• Molecular Formula: C₁₀H₁₁FO₃
• Molecular Weight: 198
• Mol File: 605680-35-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Propanoic acid, 2-(2-fluorophenoxy)-2-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2-(2-fluorophenoxy)-2-Methyl-(605680-35-1)
• EPA Substance Registry System: Propanoic acid, 2-(2-fluorophenoxy)-2-Methyl-(605680-35-1)

Safety Data

• Hazardous Substances Data: 605680-35-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Propanoic acid, 2-(2-fluorophenoxy)-2-methyl-, is used as a reactant for the preparation of substituted azoles. These azoles are specifically designed as inhibitors targeting the Hepatitis C virus. Propanoic acid, 2-(2-fluorophenoxy)-2-methylplays a crucial role in the development of antiviral drugs, contributing to the fight against Hepatitis C by disrupting the virus's replication process and limiting its ability to infect healthy cells.

Upstream product

• 367-12-4 2-fluorophenol 
• 2052-01-9 2-bromo-2-methylpropionic acid 
• 57-15-8 1,1,1-trichloro-2-methyl-2-propanol 

Downstream Products

• 1284057-53-9 C₁₀H₁₀ClFO₂ 

Relevant articles and documents

Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation

Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Hepatitis C Virus Inhibitors

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Pd(II)-catalyzed ortho - Or meta-C-H olefination of phenol derivatives

A combination of weakly coordinating auxiliaries and ligand acceleration allows for the development of both ortho- and meta-selective C-H olefination of phenol derivatives. These reactions demonstrate the feasibility of directing C-H functionalizations when functional groups are distal to target C-H bonds. The meta-C-H functionalization of electron-rich phenol derivatives is unprecedented and orthogonal to previous electrophilic substitution of phenols in terms of regioselectivity. These methods are also applied to functionalize α-phenoxyacetic acids, a fibrate class of drug scaffolds.

ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.